Amgen Inc. delivered an impressive fourth quarter for 2025, reporting revenues of $9.87 billion—an 8.6% year-on-year increase that surpassed Wall Street estimates. This strong performance, driven by robust sales of key products, triggered an over 8% rise in share price, renewing investor confidence. Despite challenges from biosimilars and anticipated sales erosion of some established drugs, Amgen's optimistic 2026 guidance of $37 billion to $38.4 billion in revenue and ongoing development in new therapies position the firm favorably in the competitive landscape.
“Amgen exceeded fourth-quarter expectations on strong sales of its biggest medicines, and forecast 2026 performance that aligns with what Wall Street is anticipating.”
“The top S&P 500 healthcare gainers and losers for the last week are as follows: Amgen (AMGN) +12.38%.”
“Thankfully, over the next few years, Amgen should earn approval for several newer products. The company's bemarituzumab, an investigational therapy for gastric cancer, performed well in phase 3 studies last year, as did rocatinlimab, a medicine for eczema.”
“Amgen is a great dividend stock, having increased its payouts every year since initiating them in 2011.”
“Amgen still has several drugs that will help pull its sales in the right direction. These include Tezspire, a medicine for asthma, and Repatha, used to lower bad cholesterol, among others.”
“Amgen (NasdaqGS:AMGN) ended its eczema drug partnership with Kyowa Kirin involving the experimental therapy rocatinlimab.”
“The company also received an FDA request to withdraw Tavneos, a treatment for a rare blood vessel disease, due to concerns about clinical trial data.”
“For you, the key takeaway is that management is willing to walk from a late-stage atopic dermatitis drug while still defending an approved rare-disease therapy, which may signal where it sees the strongest risk adjusted returns across a crowded field that includes Sanofi, Regeneron and AbbVie.”
“On February 4, RBC Capital raised its price recommendation on Amgen Inc. (NASDAQ:AMGN) to $360 from $335. The firm also kept an Outperform rating and pointed to a strong fourth quarter on both revenue and earnings.”
“A day earlier, on February 3, Amgen reported fourth-quarter results that exceeded Wall Street expectations.”
“Amgen is currently running six Phase 3 trials for MariTide across obesity and related conditions, including heart disease and sleep apnea.”
“The company also plans to begin Phase 3 studies in diabetes patients later this year.”
